Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Cash from Financing Activities (2020 - 2025)

PROCEPT BioRobotics has reported Cash from Financing Activities over the past 6 years, most recently at $4.4 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $4.4 million for Q4 2025, down 97.4% from a year ago — trailing twelve months through Dec 2025 was $11.2 million (down 93.79% YoY), and the annual figure for FY2025 was $11.2 million, down 93.79%.
  • Cash from Financing Activities for Q4 2025 was $4.4 million at PROCEPT BioRobotics, up from $1.1 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for PRCT hit a ceiling of $174.1 million in Q3 2021 and a floor of -$1.3 million in Q4 2022.
  • Median Cash from Financing Activities over the past 5 years was $2.5 million (2023), compared with a mean of $31.2 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 304.66% in 2022 and later skyrocketed 20764.74% in 2023.
  • PROCEPT BioRobotics' Cash from Financing Activities stood at $644000.0 in 2021, then tumbled by 304.66% to -$1.3 million in 2022, then soared by 317.45% to $2.9 million in 2023, then surged by 5850.03% to $170.5 million in 2024, then tumbled by 97.4% to $4.4 million in 2025.
  • The last three reported values for Cash from Financing Activities were $4.4 million (Q4 2025), $1.1 million (Q3 2025), and $4.4 million (Q2 2025) per Business Quant data.